Compare ANNX & SCSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | SCSC |
|---|---|---|
| Founded | 2011 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.1M | 869.5M |
| IPO Year | 2020 | 1997 |
| Metric | ANNX | SCSC |
|---|---|---|
| Price | $4.28 | $45.17 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 4 |
| Target Price | $17.00 | ★ $64.50 |
| AVG Volume (30 Days) | ★ 3.6M | 309.3K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.33 |
| EPS | N/A | ★ 0.42 |
| Revenue | N/A | ★ $3,846,260,000.00 |
| Revenue This Year | N/A | $12.92 |
| Revenue Next Year | N/A | $5.96 |
| P/E Ratio | ★ N/A | $108.64 |
| Revenue Growth | N/A | ★ 7.79 |
| 52 Week Low | $2.54 | $33.76 |
| 52 Week High | $7.18 | $66.78 |
| Indicator | ANNX | SCSC |
|---|---|---|
| Relative Strength Index (RSI) | 56.67 | 26.32 |
| Support Level | $3.71 | $34.23 |
| Resistance Level | $4.37 | $45.93 |
| Average True Range (ATR) | 0.26 | 2.81 |
| MACD | 0.06 | -1.88 |
| Stochastic Oscillator | 73.86 | 22.97 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.